Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges
Authors:
Open Access
- 1 December 2014
- journal article
- review article
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. 7, 7-29
Abstract
Treating pregnant women with bipolar disorder is among the most challenging clinical endeavors. Patients and clinicians are faced with difficult choices at every turn, and no approach is without risk. Stopping effective pharmacotherapy during pregnancy exposes the patient and her baby to potential harms related to bipolar relapses and residual mood symptom-related dysfunction. Continuing effective pharmacotherapy during pregnancy may prevent these occurrences for many; however, some of the most effective pharmacotherapies (such as valproate) have been associated with the occurrence of congenital malformations or other adverse neonatal effects in offspring. Very little is known about the reproductive safety profile and clinical effectiveness of atypical antipsychotic drugs when used to treat bipolar disorder during pregnancy. In this paper, we provide a clinically focused review of the available information on potential maternal and fetal risks of untreated or undertreated maternal bipolar disorder during pregnancy, the effectiveness of interventions for bipolar disorder management during pregnancy, and potential obstetric, fetal, and neonatal risks associated with core foundational pharmacotherapies for bipolar disorder.Keywords
This publication has 205 references indexed in Scilit:
- The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugsThe Journal of Pediatrics, 2005
- Malformation Rates in Children of Women with Untreated EpilepsyDrug Safety, 2004
- Epilepsy and pregnancy: lamotrigine as main drug usedActa Neurologica Scandinavica, 2003
- Costs of Bipolar DisorderPharmacoEconomics, 2003
- Treating Recurrent Affective Disorders During and After PregnancyDrug Safety, 1998
- Pattern of Malformations in the Children of Women Treated with Carbamazepine during PregnancyNew England Journal of Medicine, 1989
- Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acidThe Journal of Pediatrics, 1986
- Nephrogenic diabetes insipidus in transplacental lithium intoxicationThe Journal of Pediatrics, 1979
- TRANSPLACENTAL LITHIUM POISONING: REVERSIBLE INHIBITION OF FETAL THYROIDThe Lancet, 1975
- LITHIUM, EBSTEIN'S ANOMALY, AND OTHER CONGENITAL HEART DEFECTSThe Lancet, 1974